Related references
Note: Only part of the references are listed.Factor IX alteration p.Arg338Gln (FIX Shanghai) potentiates FIX clotting activity and causes thrombosis
Wenman Wu et al.
HAEMATOLOGICA (2021)
Preclinical evaluation of a next-generation, subcutaneously administered, coagulation factor IX variant, dalcinonacog alfa
Timothy C. Nichols et al.
PLOS ONE (2020)
Protein-Engineered Coagulation Factors for Hemophilia Gene Therapy
Benjamin J. Samelson-Jones et al.
MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT (2019)
Maturation of coagulation factor IX during Xase formation as deduced using factor VIII-derived peptides
Han Fang et al.
FEBS OPEN BIO (2019)
Hyperactive Factor IX Padua: A Game-Changer for Hemophilia Gene Therapy
Thierry VandenDriessche et al.
MOLECULAR THERAPY (2018)
Complete correction of hemophilia B phenotype by FIX-Padua skeletal muscle gene therapy in an inhibitor-prone dog model
Robert A. French et al.
BLOOD ADVANCES (2018)
Hemophilia B Gene Therapy with a High-Specific-Activity Factor IX Variant
L. A. George et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Specific factor IX mRNA and protein features favor drug-induced readthrough over recurrent nonsense mutations
Alessio Branchini et al.
BLOOD (2017)
Canine models of inherited bleeding disorders in the development of coagulation assays, novel protein replacement and gene therapies
T. C. Nichols et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2016)
Human cell lines: A promising alternative for recombinant FIX production
Aline de Sousa Bomfim et al.
PROTEIN EXPRESSION AND PURIFICATION (2016)
Inherited thrombophilia: a double-edged sword
Saskia Middeldorp
HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM (2016)
AAV liver expression of FIX-Padua prevents and eradicates FIX inhibitor without increasing thrombogenicity in hemophilia B dogs and mice
Julie M. Crudele et al.
BLOOD (2015)
In vivo efficacy of human recombinant factor IX produced by the human hepatoma cell line HuH-7
N. Enjolras et al.
HAEMOPHILIA (2015)
Employing a Gain-of-Function Factor IX Variant R338L to Advance the Efficacy and Safety of Hemophilia B Human Gene Therapy: Preclinical Evaluation Supporting an Ongoing Adeno-Associated Virus Clinical Trial
Paul E. Monahan et al.
HUMAN GENE THERAPY (2015)
Validation of the manufacturing process used to produce long-acting recombinant factor IX Fc fusion protein
J. McCue et al.
HAEMOPHILIA (2014)
Integration-deficient Lentiviral Vectors Expressing Codon-optimized R338L Human FIX Restore Normal Hemostasis in Hemophilia B Mice
Thipparat Suwanmanee et al.
MOLECULAR THERAPY (2014)
Factor IX-Padua enhances the fibrinolytic resistance of plasma clots
Concetta T. Ammollo et al.
THROMBOSIS AND HAEMOSTASIS (2014)
Translational Data from AAV-Mediated Gene Therapy of Hemophilia B in Dogs
Timothy Nichols et al.
Human Gene Therapy Clinical Development (2014)
An interactive mutation database for human coagulation factor IX provides novel insights into the phenotypes and genetics of hemophilia B
P. M. Rallapalli et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2013)
Factor IX activity/antigen ratio and the risk of first unprovoked venous thromboembolism
Elena Campello et al.
THROMBOSIS AND HAEMOSTASIS (2013)
Incorporation of the factor IX Padua mutation into FIX-Triple improves clotting activity in vitro and in vivo
Chung-Yang Kao et al.
THROMBOSIS AND HAEMOSTASIS (2013)
The efficacy and the risk of immunogenicity of FIX Padua (R338L) in hemophilia B dogs treated by AAV muscle gene therapy
Jonathan D. Finn et al.
BLOOD (2012)
Stable and high-level production of recombinant Factor IX in human hepatic cell line
Andrielle de Castilho Femandes et al.
BIOTECHNOLOGY AND APPLIED BIOCHEMISTRY (2011)
Factor IX-R338L (Factor IX Padua) screening in a Dutch population of sibpairs with early onset venous thromboembolism
Jorine S. Koenderman et al.
THROMBOSIS RESEARCH (2011)
Peripheral transvenular delivery of adeno-associated viral vectors to skeletal muscle as a novel therapy for hemophilia B
Valder R. Arruda et al.
BLOOD (2010)
Safety of AAV Factor IX Peripheral Transvenular Gene Delivery to Muscle in Hemophilia B Dogs
Virginia Haurigot et al.
MOLECULAR THERAPY (2010)
Prevalence of Factor IX-R338L (Factor IX Padua) in a cohort of patients with venous thromboembolism and mild elevation of factor IX levels
Bruna de Moraes Mazetto et al.
THROMBOSIS RESEARCH (2010)
X-Linked Thrombophilia with a Mutant Factor IX (Factor IX Padua)
Paolo Simioni et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Dramatic Increase in Venous Thromboembolism in Children's Hospitals in the United States From 2001 to 2007
Leslie Raffini et al.
PEDIATRICS (2009)
The heparin-binding exosite of factor IXa is a critical regulator of plasma thrombin generation and venous thrombosis
Yang Buyue et al.
BLOOD (2008)
Factor IX variants improve gene therapy efficacy for hemophilia B
J Schuettrumpf et al.
BLOOD (2005)
The factor IXa heparin-binding exosite is a cofactor interactive site: Mechanism for antithrombin-independent inhibition of intrinsic tenase by heparin
QP Yuan et al.
BIOCHEMISTRY (2005)
Share Paper
